Aligos Therapeutics, INC Form 4 insider transactions

Aligos Therapeutics Director Heather Preston acquired stock options for 5,860 shares of common stock.

Margarita Chavez, a Director at Aligos Therapeutics, Inc., acquired stock options for 5,860 shares of common stock.

Aligos Therapeutics Director Bridget A. Martell acquired stock options for 5,860 shares of common stock.

James Paul Scopa, a Director at Aligos Therapeutics, Inc., acquired stock options for 5,860 shares of common stock on June 25, 2026.

Carole Nuechterlein, a Director at Aligos Therapeutics, Inc., was granted a stock option for 5,860 shares of common stock.

Aligos Therapeutics Director Peter Hirth acquired 5,860 stock options with an exercise price of $5.50, vesting fully on the first anniversary of the grant date or before the 2027 annual meeting.

Aligos Therapeutics, Inc. President and CEO Lawrence Blatt was granted 179,800 stock options with an exercise price of $8.68, vesting monthly over four years.

Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, Inc., was granted 16,000 stock options with an exercise price of $8.68 per share, vesting over four years.

Aligos Therapeutics, Inc. has granted 40,185 stock options to its Chief Operating Officer and Chief Financial Officer, Lesley Ann Calhoun, with an exercise price of $8.68 per share.

Aligos Therapeutics, Inc. Director Carole Nuechterlein was granted 5,860 stock options with an exercise price of $7.63, vesting on the earlier of the first anniversary of the grant date or prior to the 2026 annual meeting.

Aligos Therapeutics, Inc. Director James Paul Scopa was granted 5,860 stock options with an exercise price of $7.63 per share, vesting over the next year.

Aligos Therapeutics, Inc. Director Peter Hirth was granted 5,860 stock options with an exercise price of $7.63, which will vest fully by the earlier of June 25, 2026, or the company's 2026 annual meeting.

Aligos Therapeutics, Inc. Director Heather Preston was granted 5,860 stock options with an exercise price of $7.63, vesting over the next year.

Aligos Therapeutics, Inc. Director Margarita Chavez was granted 5,860 stock options with an exercise price of $7.63, vesting by mid-2026.

Aligos Therapeutics, Inc. Director Bridget A Martell was granted 5,860 stock options with an exercise price of $7.63, vesting on the earlier of one year from grant or prior to the 2026 annual meeting.

Aligos Therapeutics' CEO, Lawrence Blatt, was granted 140,103 stock options on February 28, 2025, according to a Form 4 filing with the SEC.

Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, reported the grant of a stock option to purchase 21,693 shares of common stock on February 28, 2025.

Lesley Ann Calhoun, Chief Operating Officer and Chief Financial Officer of Aligos Therapeutics, acquired stock options for 47,271 shares on February 28, 2025.

Hardean Achneck, Chief Medical Officer of Aligos Therapeutics, acquired 75,000 stock options on October 8, 2024, according to a Form 4 filing with the SEC.

Lesley Ann Calhoun, CFO of Aligos Therapeutics, acquired stock options on September 4, 2024.

Lawrence Blatt, CEO of Aligos Therapeutics, acquired stock options for 33,920 shares of common stock on September 4, 2024, according to a Form 4 filing.

Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, Julian A. Symons, reports the acquisition of stock options.

Director Margarita Chavez acquired stock options for 120,000 shares of Aligos Therapeutics at an exercise price of $0.55 on August 7, 2024.

Director Heather Preston acquired 120,000 stock options in Aligos Therapeutics, Inc. on August 7, 2024.

Director Peter Hirth acquired 60,000 stock options in Aligos Therapeutics, Inc. on June 27, 2024.

Director Carole Nuechterlein of Aligos Therapeutics acquired 60,000 stock options on June 27, 2024, according to a recent SEC filing.

Director James Paul Scopa reports the acquisition of stock options in Aligos Therapeutics.

Director Bridget Martell reports receiving a stock option grant for 60,000 shares of Aligos Therapeutics, Inc.

Matthew W. McClure, Chief Medical Officer of Aligos Therapeutics, acquired 72,000 stock options on March 1, 2024.

Lesley Ann Calhoun, CFO of Aligos Therapeutics, reports the acquisition of stock options.